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The use of biomonitoring data holds a great
deal of promise for characterizing exposure
and informing risk assessment. Biomonitoring
data have been used successfully to track
population trends, to identify susceptible sub-
populations, to evaluate progress in reducing
exposures, and to provide indications of
emerging environmental health issues.
However, there are significant challenges
associated with interpreting biomonitoring
data for risk assessment and for understand-
ing the public health implications of meas-
ured body burdens. For example, information
on exposure pathways is often required to
link biomonitoring results to contaminant
sources and to reduce exposures and risks. An
international biomonitoring workshop was
convened in September 2004 to explore the
use of biomonitoring data in the context of
risk assessment with an emphasis on linking
measured body burdens to exposure, internal
dose, and potential health outcome (Albertini
et al. 2006). Six compounds were examined
as case studies for this workshop: inorganic
arsenic (Hughes 2006), methyl eugenol
(Robison and Barr 2006), organophosphorus
pesticides (Barr and Angerer 2006), per-
ﬂuorooctanesulfonate (Butenhoff et al. 2006),
phthalates (Calafat and McKee 2006), and
polybrominated diphenyl ethers (PBDEs).
These case studies were selected based on the
properties of the compounds and on the
richness of associated data in order to explore
the potential and limitations of using bio-
monitoring data to inform human exposure
health risk assessment. The PBDE case study
was developed to provide an example of a
compound that is relatively stable in the envi-
ronment, with the potential to bioaccumulate
but for which relatively few human exposure,
biomonitoring, and health outcome data
are available.
The presence and steady increase in envi-
ronmental and human concentrations of
PBDEs have heightened interest in the poten-
tial toxicologic consequences of these chemi-
cals (Birnbaum and Staskal 2004; de Wit
2002). Our overall objective of this article is to
discuss the use of biomonitoring data in
understanding potential human health risks
from exposures to PBDEs. We begin by giving
a summary of the properties and uses of
PBDEs. We also discuss PBDE biomarkers
and the analytical methods for measuring
these. Next, we highlight important data and
ﬁndings on human exposure, pharmacokinet-
ics, toxicity, and biomarker levels. Although
currently available data in these areas are lim-
ited, new data are rapidly emerging. Therefore,
we conclude by discussing some of the risk
assessment and public health uses for these
data and identifying significant gaps that
should be addressed to improve interpretation
of PBDE biomonitoring data.
Properties and Uses of PBDEs
PBDEs have the general chemical formula
C12H(9–0)Br(1–10)O, with the sum of H and Br
atoms always equal to 10. The general structure
is given in Figure 1. All PBDEs present in com-
mercial products have low water solubility
(< 1 µg/L) and high log octanol–water partition
coefﬁcient (Kow) values (> 5). The lower bromi-
nated congeners have higher vapor pressures
than the higher brominated compounds
(Birnbaum and Staskal 2004; de Wit 2002).
PBDEs theoretically comprise 209 con-
geners divided into 10 homolog groups
(mono- to decabromodiphenyl ethers). There
are three major commercial products with 
an average of 5 [pentabromodiphenyl ether
(PeBDE), “Penta”], 8 [octabromodiphenyl
ether (OBDE), “Octa”], or 10 [decabromo-
diphenyl ether (DBDE), “Deca”] bromines.
Congeners with fewer than 4 bromines are
rarely found in the commercial mixtures
(Darnerud et al. 2001). PBDEs are numbered
according to the International Union of Pure
and Applied Chemistry (IUPAC) system orig-
inally used for polychlorinated biphenyls
(PCBs). However, there are fewer congeners
in the PBDE mixtures, as for polybrominated
biphenyls (PBBs), than in the PCB mixtures.
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Figure 1. General PBDE structure.
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Ring B Ring A (n = 0 to 10)PBDEs are added globally to a variety 
of consumer goods as flame retardants.
Approximately 66,000 metric tons of PBDEs
were used worldwide in 2001 [Bromine
Science and Environmental Forum (BSEF)
2004]. Deca has the largest global production,
with Octa being a relatively small component
of the worldwide PBDE production. Penta is
used primarily in North America. Although
the chemical composition of the commercial
Deca mixture is primarily (> 97%) DBDE
(BDE-209) along with a small amount of
nonabrominated diphenyl ethers (NBDEs)
and OBDEs, the Octa and Penta commercial
mixtures are more complex. Octa contains
approximately 10–12% hexabrominated
diphenyl ethers (HxBDEs), 44% heptabromi-
nated diphenyl ethers (HpBDEs), 31–35%
OBDEs, 10–11% NBDEs, and < 1% DBDE.
The commercial Penta mixtures have had
more variability but generally have contained
24–38% tetrabromodiphenyl ethers (TBDEs),
40–60% PeBDEs, and 4–8% HxBDEs
[World Health Organization (WHO) 1994].
The major congeners in Penta are IUPAC
congeners 47 and 99, which account for
approximately 75% of the total mass, with
approximately twice as much BDE-99
(PeBDE) as BDE-47 (TBDE). There are
approximately equal amounts of BDE-153
and BDE-154 (HxBDEs), similar to that of
BDE-100 (PeBDE) (WHO 1994). Octa and
Penta were formally banned in Europe as of
August 2004. The sole U.S. producer volun-
tarily agreed to stop production of Octa and
Penta at the end of 2004. The structures and
IUPAC numbers for common PBDEs are pre-
sented in Table 1.
The commercial mixtures have different
uses, but all are additive flame retardants
(BSEF 2004). Penta is primarily used in ﬂexi-
ble polyurethane foam, where it can account
for as much as 30% by weight (Hale et al.
2003). Minor uses include ﬂame retardancy in
phenolic resins, polyesters, and epoxy resins.
Octa is used as an additive in polymers for use
in plastic housing and ofﬁce equipment. Deca
is used in high-impact polystyrene and as a
polymer backcoating on commercial textiles
and is added to a wide variety of polymers
used in electrical and electronic equipment.
Biomarker of Exposure
Several studies have demonstrated that the
PBDEs partition into body lipids. Similar results
are obtained from blood, serum, cord blood,
breast milk, and adipose tissue if measurements
are normalized to lipid (Hites 2004). There are
no reports of PBDE measurements in urine.
Because of their persistence and bio-
accumulation, measurement of BDE con-
geners in biologic specimens is a good marker
of exposure. To date, little attention has
focused on measuring potential BDE metabo-
lites as biomarkers.
Measurement of PBDE congeners usually
requires high-resolution gas chromatography/
mass spectrometry techniques. Under most
measurement conditions, most congeners can
be detected below the parts-per-billion range.
However, because of the ubiquitous presence
of Deca, there are problems with laboratory
contamination with BDE-209, and special care
must be taken. In addition, because there are
so many potential congeners, it is essential that
standards be used and the identity of speciﬁc
congeners conﬁrmed. For human samples, val-
ues are usually reported on a lipid-adjusted
basis. This allows comparison across various
matrices, such as blood, breast milk, and adi-
pose tissue. This is not always done for animal
samples, where wet weight is often used. Often
to estimate intake from food, it is more impor-
tant to know the wet weight.
Exposure Assessment
Until very recently, data were not available to
attempt a mass-balance comparison of meas-
ured body burden levels with exposure esti-
mated indirectly from information on product
use, measurements in environmental media,
and human activity and pharmacokinetics.
Such an analysis would still be difficult
because of limited availability of data, variabil-
ity in body burdens, and lack of information
on the fate and transport of the commercial
products and the PBDE congeners.
Recent studies have demonstrated that
PBDE congeners have been detected in all
people measured in North America, at levels
of 5–10,000 ng/g lipid. The average levels are
approximately 10 times those in Europe or
Asia, where the range of measured PBDE con-
geners is 1–10 ng/g lipid. Based on the avail-
able data, there appears to be much greater
variability (approximately a 100-fold range) in
the lipid-adjusted levels than observed for
other persistent organic pollutants. For exam-
ple, although 5% of the general population
has lipid-adjusted concentrations of dioxins
and PCBs that are double the mean, and 1%
has concentrations that are triple, 5% of the
population has concentrations of PBDEs 
at least 10 times the average (Schecter et al.
2003).
The wide variation in human levels intro-
duces some questions about exposure assess-
ment using biomarkers. Although BDE-47,
the major congener found in people, is very
persistent in the rat, it is rapidly eliminated
unchanged in the urine of mice (Orn and
Klasson-Wehler 1998). Recent studies from
Staskal et al. (2005) have suggested that
BDE-47 may be a substrate for an active trans-
port system in the kidney and/or may be
highly bound to urinary proteins.
The PBDEs are always present as mixtures.
Because there is growing evidence for the abil-
ity of both photolytic (Soderstrom et al. 2004)
and biotic (Stapleton et al. 2004) debromina-
tion to occur, it is impossible to determine for
sure which PBDE product is responsible for
the general population exposure. In addition,
many published studies have measured only a
very limited number of congeners, and the
choice has not been consistent. Butt et al.
(2004) have shown that BDE-209 is the major
PBDE in air and on window ﬁlms; previously,
it was not often measured. Similarly, some
human studies have examined only BDE-47
(e.g., Petreas et al. 2002) or a limited number,
including BDE-99, BDE-100, BDE-153, and
BDE-154 (e.g., Mazdai et al. 2003), with no
measures of higher brominated species that
could come from Octa or Deca mixtures.
The congener pattern downstream of pro-
duction and/or use facilities often resembles
the commercial mixture (Hale et al. 2001,
2003). However, because these compounds
persist and bioaccumulate up the food chain,
the patterns of congeners evolve (Alaee et al.
2002). Although the ratio of BDE-99 to
BDE-47 is nearly 2 in the commercial Penta
product, in most human samples, this ratio is
inverted (e.g., Schecter et al. 2003). In some
marine mammals high on the food chain such
as ring seals in northern Canada, the levels of
BDE-99 are barely 1/10th of those of BDE-47
(Ikonomou et al. 2002). This is likely due to
metabolism of BDE-99 because it has been
shown to be well absorbed and converted to
hydroxy and debrominated hydroxy metabo-
lites (Hakk et al. 2002). In addition, the rela-
tive amounts of several other penta and hexa
congeners change. Whether these changes are
due to metabolism and clearance or are the
result of debromination from the Octa and
Deca mixtures remains to be determined. 
Indirect estimates of exposure have been
conducted by industry under the Voluntary
Children’s Chemical Evaluation Program for
the U.S. Environmental Protection Agency
(Toxicology Excellence for Risk Assessment
2003a, 2003b). These estimates focused on
exposure to children but did include some
occupational estimates. Unfortunately, these
PBDE case study
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Table 1. Most often measured PBDE: IUPAC num-
bers and structures.
IUPAC number Bromine substitution structure
17 2,2´,4
28 2,4,4´
47 2,2´,4,4´
66 2,3´,4,4´
77 3,3´,4,4´
85 2,2´,3,4,4´
99 2,2´,4,4´,5
100 2,2´,4,4´,6
138 2,2´,3,4,4´,5´
153 2,2´,4,4´,5,5´
154 2,2´,4,4´,5,6´
183 2,2´,3,4,4´,5´,6
209 2,2´,3,3´,4,4´,5,5´,6,6´exposure estimates were based on European
air, soil, and food levels, which are much lower
than those observed in the United States.
There is very limited information concern-
ing the source–exposure–dose continuum.
Little quantitative information is known
regarding how the PBDEs are entering the
environment, although hypotheses include
leakage at site of use and incorporation into
products, during use of the products, and dur-
ing destruction. Exposures have been studied
for workers involved in manufacturing PBDEs
or handling products containing ﬂame retar-
dants (Sjodin et al. 1999, 2001; Thuresson
et al. 2005). PBDEs can be found in sediment
downstream of use sites (Hale et al. 2003).
PBDEs have been measured in air, at higher
concentrations in rooms with electronics
equipment, and in dust where equipment as
well as furniture and heavy textiles are present.
Recently, several studies have measured PBDE
concentrations in various foods (Harrad et al.
2004; Huwe et al. 2002b; Schecter et al.
2004), including ﬁsh (Hites et al. 2004). In the
United Kingdom (Harrad et al. 2004), esti-
mates of daily intake are 2 ng/kg/day, similar
to what has been estimated in Spain (Bocio
et al. 2003). Schecter et al. (2004) published
the ﬁrst preliminary study of supermarket food
in the United States. Calculations based on this
information suggest that daily intake varies by
age. Nursing infants may be exposed to
150 ng/kg/day due to lactational off-loading,
whereas most adults would consume approxi-
mately 1–2 ng/kg/day “total” PBDEs (sum of
13 congeners). Wilford et al. (2004) measured
the lower brominated PBDE congeners in
indoor and outdoor air in Canada. On the
basis of median PBDE levels found in this
study, the authors estimate that approximately
4% of overall daily intake is the result of
inhalation exposures. These limited data sug-
gest that foods of animal origin are a signiﬁcant
source of human exposure, but inhalation and
dust may also be important. In fact, a recent
report from Webster et al. (2005) demon-
strates a clear association between the sum of
the ﬁve major lower brominated congeners in
breast milk and those in house dust.
Pharmacokinetics
General information. PBDEs can break down
at high temperatures. These also undergo
ultraviolet (UV)-catalyzed debromination
(Soderstrom et al. 2004). Although earlier
studies had indicated that the rate of debromi-
nation was inversely related to the degree of
bromination, with DBDE breaking down
most rapidly, at least in organic solvents,
recent studies have demonstrated that this
breakdown also occurs in sand and sediment.
BDE-47 could be produced in the presence of
organic solvents from BDE-209 with UV
light, as could multiple penta, hexa, hepta,
octa, and nona congeners (Soderstrom et al.
2004). Anaerobic microbial degradation of
Deca also appears to occur, although relatively
slowly (Gerecke et al. 2005). The congener
composition found in biota rarely mimics that
found in the commercial mixtures: not only
are congeners detected that have not been
reported in the commercial mixtures, but the
ratios of congeners change (Hites 2004). For
example, although the ratio of BDE-99 to
BDE-47 is nearly 2 in the commercial Penta
mixture, there is almost twice as much
BDE-47 as BDE-99 in human breast milk
(Schecter et al. 2003).
Penta-speciﬁc information. A commercial
Penta product was given orally to rats, and
the half-life of individual congeners was deter-
mined in adipose tissue (Von Meyerink et al.
1990). Half-lives were 19–30 days for TBDE,
42–25 days for PeBDEs, and 50–105 days
for HxBDEs.
To date, there have been two toxicokinetic
studies published for BDE-99 in rats (Chen
et al. 2006; Hakk et al. 2002), demonstrating
that this congener is well absorbed, distributed
to lipid-rich tissues, and metabolically elimi-
nated. Orn and Klasson-Wehler (1998) stud-
ied the fate of BDE-47 in both mice and rats
after a single oral dose. Although its behavior
was as expected in rats (well absorbed, distrib-
ution to adipose and liver, long half-life, elimi-
nation in feces, limited metabolism), the
parent compound was rapidly eliminated in
the urine of mice. These results have been
conﬁrmed by Staskal et al. (2005) in another
strain of mouse and by Sanders et al. (2006) in
rats. Staskal and co-workers have also demon-
strated that the pharmacokinetic behavior of
BDE-47 is dose dependent, with relative elim-
ination decreasing as the dose is raised. They
have shown that BDE-47 is well absorbed
after oral, intratracheal, and intraperitoneal
exposure (> 80%) and that dermal absorption
is > 60%. Less than 5% of an administered
dose remains in the mice 21 days after treat-
ment, but the terminal half-lives are longer
than 20 days, suggesting some potential for
bioaccumulation. Elimination is consistently
greater in urine than in feces and is primarily
protein-bound unmetabolized BDE-47
(Staskal DF, Birnbaum LS, personal commu-
nication). Pharmacokinetic behavior changes
as a function of age that could explain the
increased susceptibility to developing animals
(Eriksson et al. 2002).
Octa-speciﬁc information. Limited studies
have been conducted on the commercial Octa
mixture (Huwe et al. 2002a).
Deca-speciﬁc information. Several studies
have suggested that BDE-209 is poorly
absorbed, both from the gastrointestinal tract
[National Toxicology Program (NTP) 1986]
and from the skin (Hughes et al. 2001).
However, recent studies have indicated that
DBDE can be absorbed by the rat with
bioavailability of approximately 26% when a
suitable vehicle was used (Morck et al. 2003).
Approximately 10% of the administered dose
was eliminated as metabolites via the bile.
Hydroxylated NBDEs and OBDEs were pro-
duced, demonstrating debromination. The
terminal half-life was surprisingly short:
2.5 days. This may be a reflection that peak
concentrations were not reached in the rat
during the course of this short study because
there was no evidence of high concentrations
of BDE-209 in adipose tissue, which is nor-
mally a major depot for such a lipophilic com-
pound. In fact, in a long-term feeding study in
rats using the commercial Deca mixture,
retention was observed in fat (Kociba et al.
1975). Once again, uptake and retention may
vary as a function of age. In newborn mice the
uptake of DBDE is as high as for PeBDE
(Viberg et al. 2003b).
Human data. Recently, Geyer et al. (2004)
estimated terminal elimination half-lives in
humans for BDE-47, BDE-99, BDE-100,
BDE-153, and BDE-154. The half-lives esti-
mated from body burden and daily intake
(based on market basket survey in Sweden)
were on the order of 2–3 years, with the excep-
tion of BDE-153 for which estimated half-lives
were on the order of 4–6 years or more. These
estimates assumed gastrointestinal absorption
from food of 86–96%. Estimates of half-lives
in human fat extrapolated from measured half-
lives in the fat of rats were signiﬁcantly greater.
Higher brominated congeners appear to have
shorter half-lives. Thuresson et al. (2006)
reported apparent half-lives in human serum of
11–18, 18–39, and 37–91 days for deca, nona,
and octa BDEs, respectively.
Toxicity Data
Animal toxicity. General information. Limited
studies have been conducted concerning the
ecologic effects of PBDE (Birnbaum and
Staskal 2004; Birnbaum et al. 2003). None of
the commercial mixtures are genotoxic. In gen-
eral, Penta is more toxic than Octa, whereas
Deca is essentially nontoxic to invertebrates.
Recent studies have shown Penta to be devel-
opmentally toxic to ﬁsh (Timme-Laragy et al.
2006). Mammalian toxicity studies have been
conducted on all three commercial mixtures,
and in general, relatively high doses are
required for overt toxicity in adults. However,
there is growing concern for developmental
and endocrine effects. Limited information is
available on congener-speciﬁc effects. A grow-
ing concern is their structural similarity to
other polyhalogenated aromatic hydrocarbons,
such as PCBs and dioxins (Darnerud et al.
2001). The commercial mixtures contain
dioxin-like contaminants (Sanders et al. 2005),
which may also be generated upon burning.
Although some PBDE congeners may have
Birnbaum and Cohen Hubal
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the congeners that are found in environmental
samples and biota are not dioxin-like (Chen
et al. 2001).
Penta-specific information. Penta has
been implicated in hepatic and endocrine-
related effects after repeated exposure but has
relatively low acute toxicity. The commercial
Penta can induce both phase I and phase II
hepatic enzymes. Penta exposure leads to a
decrease in serum thyroxine levels (Zhou et al.
2002), as does exposure to BDE-47 or
BDE-99. In fact, decreases in thyroxine have
been reported in mice after a single dose of
0.8 mg Penta/kg (Fowles et al. 1994). Several
mechanisms have been proposed for these
effects, including induction of hepatic glu-
curonyl transferases (Zhou et al. 2001) and
binding to transthyretin (Meerts et al. 2001).
There are some reports of immunotoxicity
from Penta, but this is likely due to dioxin-like
contaminants in the mixture.
Developmental reproductive effects occur
after maternal exposure. These include delays
in puberty and decreases in sex organ weights.
Recent reports have indicated that Penta, as
well as the major PBDE congeners that com-
pose it, may be antiandrogenic (Stoker et al.
2004, 2005). Other experimental work has
suggested that certain PBDEs or their metabo-
lites may be estrogenic or antiestrogenic
(Lilienthal et al. 2006; Meerts et al. 2001).
The greatest toxicity concern is the poten-
tial for Penta as a developmental neurotoxi-
cant. A handful of studies have demonstrated
alterations in both rats and mice. An extensive
series of studies from the laboratory of
P. Eriksson at Uppsala University in Sweden
(Eriksson et al. 2001; Viberg et al. 2002,
2003a, 2003b, 2006) has shown that
BDE-47, BDE-99, BDE-153, and BDE-209
impair spontaneous motor activity, impair
cholinergic transmitters, and disrupt habitua-
tion. These results suggest negative effects on
learning and memory that worsen with age.
This group of researchers also deﬁned a criti-
cal window of susceptibility that occurs dur-
ing a period of rapid brain growth: when
exposed on postnatal day 10, the afore-
mentioned effects ensue, most of which are
not reversible and often worsen with age.
Specifically, BDE-99 has been shown to be
developmentally neurotoxic in at least three
strains of mice and in both genders. Branchi
et al. (2003), Kuriyama et al. (2005), and
Talsness et al. (2005) also saw effects of
BDE-99 after developmental exposure of
mice and rats. Developmental neurotoxicity
has also been reported in rats, but relatively
high gestational and lactational exposures 
to commercial Penta were required. This is
reminiscent of the situation with PCBs where
developmental neurotoxicity is observed at
lower doses in mice than rats. Penta has also
been shown to affect neuronal cell signaling
in vitro (Kodavanti and Derr-Yellin 2002;
Mariussen and Fonnum 2003).
There are no chronic studies of Penta.
However, the NTP has plans to conduct
2-year studies of both the commercial mixture
and the three individual congeners, BDE-47,
BDE-99, and BDE-153 (NTP 2006).
Octa-specific information. Octa has low
acute toxicity; effects are generally observed in
liver and endocrine tissue after exposure. In a
single developmental study, Octa led to fetal
toxicity in the rat at doses below those at which
effects were seen in the dams (WHO 1994).
Effects were observed in developing rabbits at a
dose of 2 mg/kg to the mother. BDE-153, a
congener present in Octa, has been shown to
be developmentally neurotoxic (Viberg et al.
2003a). No chronic studies have been reported
on Octa.
Deca-specific information. The NTP
(1986) has conducted extensive acute and
chronic studies on Deca in both rats and mice.
High doses (up to 50,000 ppm in the diet)
resulted in liver tumors in rats and male mice.
There was some indication of an increase in
thyroid gland tumors. Deca had few other
effects (Darnerud 2003). However, BDE-209
has been shown to be developmentally neuro-
toxic (Viberg et al. 2003b).
Human toxicity. There are almost no data
on the toxicity of PBDEs in humans. There is
no evidence for Deca causing skin sensitization
(WHO 1994). There was some evidence of
primary hypothyroidism and reduction in
nerve conduction velocities after occupational
exposure to both PBDEs and PBBs (Bahn
et al. 1980). In male ﬁsh eaters from the Baltic,
Hagmar et al. (2001) concluded that their
results did not support a role in adult men for
dietary exposure to persistent organochlorines,
including BDE-47, and effects on peripheral
hormone levels, including thyroid, were not
observed. A small study (n = 12) also failed to
show any association between PBDE levels and
thyroid hormones (Mazdai et al. 2003).
Environmental Public Health
Use of Biomonitoring Data
Currently, our ability to use PBDE biomoni-
toring data to address risk assessment and
public health questions varies based on the
particular questions we are trying to answer.
Because the BDEs congeners can be measured
directly in biologic tissues, biomonitoring has
been used effectively to measure human body
burdens and to identify exposure to PBDE
as a potentially important environmental
health issue.
Characterizing the exposures that are result-
ing in measured body burdens has been more
difficult. Because PBDEs occur as mixtures,
understanding the changes in congener ratios
from sources to exposure media to internal dose
(i.e., the fate and transport of PBDEs in the
environment) is required to assess exposure.
Currently, little is known about the sources of
human exposure and how PBDEs are entering
the environment. Additional environmental
monitoring data (particularly data collected
concurrently with biomonitoring data) would
help to identify sources of exposure to better
focus future environmental health studies.
On the other hand, biomonitoring of
PBDEs has been effective for demonstrating
potential trends in exposure. The levels of
PBDEs have increased exponentially since the
early 1970s. Although this trend peaked in
Sweden in the late 1999s (Meironyte et al.
2001), levels continue to increase in North
America. Recent studies have demonstrated
that the median body burdens, based on lipid
adjustment, are approximately 10 times
higher in the United States than in Europe
(Hites 2004; Sjodin et al. 2004). People with
the lowest concentrations in the United States
are more highly exposed (internally) than
people with the highest exposure levels in
Europe today. These data can also be used to
characterize population variability. In both
the North American and European popula-
tions there is a wide range of body burdens.
Unlike PCBs and dioxins, approximately 5%
of the population has levels 10 times the
mean PBDE concentration, and 1% are as
much as 50 times the mean (Environmental
Working Group 2003). Whether this unusu-
ally broad range is due to differential exposure
within the general population or to biologic
mechanisms remains to be determined. In
addition, very limited European data indicate
that young children have signiﬁcantly higher
BDE levels than do adults. Thus, more exten-
sive biomonitoring at the population level is
required to determine reference levels and to
characterize vulnerable populations such as
children. The lack of biomonitoring data in
children is likely related to the current
requirement for blood or adipose tissue to
measure BDE congeners. Development of
PBDE biomarkers in urine would facilitate
study of children.
In addition to being used to characterize
exposure, biomonitoring data are often used to
link exposure with potential adverse health
outcomes. Given the understanding that inter-
nal dose is the best metric for relating dose to
response, the body burden measurements from
biomonitoring offer the most appropriate
approach for relating the levels in humans to
those in experimental animals in which effects
have been observed. This approach is most
effective for persistent, bioaccumulating toxi-
cants such as the PBDEs.
Multiple health effects have been reported
in experimental animals after exposure to com-
mercial PBDE mixtures, as well as exposure to
several of the most important congeners.
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as the point of departure for risk assessment
remain to be determined. In general, develop-
mental neurotoxicity appears to be an
extremely sensitive end point, at least in mice.
Recent studies suggest that developmental
reproductive effects may have similar sensitiv-
ity, as do effects on thyroid hormones. In mice,
these effects have been observed after a single
dose of < 1–10 mg/kg. Assuming that absorp-
tion is > 80%, this would lead to a body bur-
den at the critical window of < 0.8–8 mg/kg.
The most highly exposed person to date has a
body burden of approximately 1.5 ng/g lipid,
equivalent to approximately 0.3 ng/g or
0.3 mg/kg. Comparison of the body burdens
in highly exposed people with those in affected
mice suggests that the margin of exposure
could be < 10.
Finally, there have been no large-scale
epidemiology studies for PBDEs and effects
in humans are unknown. To better under-
stand the potential public health implica-
tions of available PBDE biomonitoring data,
additional study is required. Significant
insight could be obtained from additional
information on environmental fate and
transport of PBDE congeners, as well as
population-based biomonitoring data for
adults and for potentially vulnerable popula-
tions such as children.
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